Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Neutral Rating at Wedbush

Wedbush reiterated their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $4.00 price target on the stock.

ZNTL has been the subject of a number of other research reports. UBS Group dropped their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $1.81 on Friday. The stock has a market cap of $129.98 million, a price-to-earnings ratio of -0.73 and a beta of 1.75. The company has a 50 day moving average of $2.04 and a 200-day moving average of $2.85. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. Equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Voya Investment Management LLC raised its position in Zentalis Pharmaceuticals by 14.1% in the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after buying an additional 7,058 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock worth $105,000 after acquiring an additional 7,305 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth $37,000. Finally, Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $32,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.